Calcium and Aspirin Supplementation for Prevention of Preeclampsia (in High Risk Pregnancy)

/A0 sites130 target enrollmentOctober 1, 2022

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Pregnant women with one or more high risk and women with two or more moderate risk of developing preeclampsia
Sponsor: /A
Enrollment: 130
Status: Terminated
Last Updated: last year

No summary available.

Registry

who.int

Start Date

October 1, 2022

End Date

April 5, 2022

Last Updated

last year

Study Type

Interventional

Sex

Female

Sponsor

•Those who have one or more high\-risk or two or more moderate risks of developing pre\-eclampsia High risk of developing pre\-eclampsia was defined as a pregnant woman with multifetal gestation, chronic hypertension, type 1 or type 2 diabetes, renal disease, autoimmune disease (e.g., systemic lupus erythematosus and antiphospholipid syndrome), and a history of pre\-eclampsia. Moderate risk was defined as women with nulliparity, obesity with body mass index more than 30 kg/m2, family history of pre\-eclampsia, age 35 years or older, personal history factors (e.g., low birthweight or small for gestational age, previous adverse pregnancy outcome, more than 10\-year pregnancy interval)

•Exclusion criteria were patients with a history of kidney or ureteric stone, parathyroid disorders, untreated nasal polyp, aspirin\-induced bronchospasm, gastrointestinal or urinary hemorrhage, severe liver disease, hypercalcemia (serum corrected calcium level more than 10\.5 mg/dL), allergic to aspirin or CaCO3, and other underlying diseases already receiving aspirin or calcium supplementation.